Eurofins Scientific (ENXTPA:ERF) has drawn fresh attention after completing a share buyback program totalling 7,029,661 shares, or 3.97% of its capital, for €414.45 million announced in April 2025. See our latest analysis for Eurofins Scientific. The buyback comes amid a mixed price backdrop for Eurofins Scientific, with the 90 day share price return up 7.44% but the 1 year total shareholder return down 2.29%. This points to improving short term momentum following a tougher longer period. If...

Eurofins Scientific stock has delivered a decline of 28.9% over the past 5 years, yet a Discounted Cash Flow (DCF) intrinsic value estimate currently points to the shares trading at a 47.7% discount to that model, creating a valuation gap for investors to assess. Over 5 years the share price is down 28.9%, which means long term holders have not yet seen a recovery from earlier levels. The planned acquisition of Element Materials Technology’s Life Sciences Testing Services business in North...

Eurofins Scientific SE (ERFSF) reports a robust 29% EPS growth and significant margin improvements, despite facing FX headwinds and challenges in the biopharma sector.

Wondering if Eurofins Scientific at €59.34 is offering good value right now, or if the recent price leaves limited upside? This article breaks down what the current market price might be implying. The stock is up 0.5% over the last week, while the 30 day return is a 9.1% decline and the year to date return is a 4.3% decline. This is set against a 6.6% gain over the past year and 4.1% over three years, but a 22.8% decline over five years. Recent coverage has focused on Eurofins Scientific as...

UL Solutions Inc. (NYSE:ULS) is one of the best IPO stocks to buy in 2026. On April 13, UL Solutions entered into a definitive agreement to acquire the Electrical & Electronics/E&E business of Eurofins Scientific for an enterprise value of ~€575 million ($670 million). The deal includes the well-known MET Labs certification mark and is […]

Why Eurofins Scientific (ENXTPA:ERF) is back on investor radars Eurofins Scientific (ENXTPA:ERF) has drawn fresh attention after cancelling 6,163,000 previously repurchased shares, trimming its share capital, while also reporting ongoing buybacks and disclosures of share acquisitions linked to senior management. See our latest analysis for Eurofins Scientific. The share cancellation and ongoing buybacks come as Eurofins Scientific’s share price has a 1-day share price return of 2.83% and a...

Why Eurofins Scientific Is On Investors’ Radar Today Eurofins Scientific (ENXTPA:ERF) is drawing fresh attention after recent share price moves, with the stock showing mixed returns over the past week, month and past 3 months, against a backdrop of steady reported revenue and net income figures. See our latest analysis for Eurofins Scientific. At a share price of €63.52, Eurofins Scientific has seen a 6.6% decline over the past month. However, an 11.9% 90 day share price return and a 23.0% 1...

Eurofins Viracor BioPharma Services announced an expansion of its bioanalytical testing capabilities. The move includes integrating Eurofins Pharma Bioanalytics Services into a newly purpose-built facility. The integration is intended to support a broader and more connected service offering for biopharmaceutical development clients. For investors watching Eurofins Scientific (ENXTPA:ERF), this update sits squarely in the company’s core line of work, supporting drug and biologics development...